China Nuokang Bio (NKBP)

Currency in USD
3.650
0.000(0.00%)
Closed·
Showing China Nuokang Bio historical data. For real-time data please try another search
Day's Range
3.6503.720
52 wk Range
0.0003.720
Key Statistics
Prev. Close
3.65
Open
3.72
Day's Range
3.65-3.72
52 wk Range
0-0
Volume
-
Average Volume (3m)
39.28K
1-Year Change
-34.12%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

China Nuokang Bio Company Profile

China Nuokang Bio-Pharmaceutical Inc., a biopharmaceutical company, engages in the research, development, manufacture, marketing, and sale of hospital-based medical products in China. The company’s principal products include Baquting, a hemocoagulase product derived from Bothrops atrox venom to treat and prevent bleeding; and Kaitong, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders, and post-surgery thrombosis. It also offers Aiduo, a cardiovascular stress imaging agent; and Aiwen, an anti-arrhythmic agent for the diagnosis and treatment of paroxysmal supraventricular tachycardia, as well as provides dipyridamole aspirin capsules for the prevention of strokes. In addition, the company’s products under development comprise a hemocoagulase derived from Agkistrodon acutus snake venom; lanthanum polystyrene sulfonate product candidate for the treatment of hyperphosphatemia; and adenosine as a myocardial protection agent for various cardiovascular-related clinical settings. Further, its product pipeline includes product candidates under development that address the medical needs for bleeding control and hematological, cardiovascular, and cerebrovascular disease diagnosis, treatment, and prevention. It sells its products to pharmaceutical distributors. China Nuokang Bio-Pharmaceutical Inc. was founded in 1997 and is based in Shenyang, China. As of February 7, 2013, China Nuokang Bio-Pharmaceutical Inc. was taken private.

Employees
454

Earnings

Latest Release
Feb 27, 2019
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NKBP Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.